RxDoctor Payments Data

Justin Hebert

Interventional Pain Medicine · Pensacola, FLNPI 1356704308

Payments from drug & device makers

$5,391in general payments, 2019–2025

Across 81 payments — averaging $66.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$643
  • Abbott$595
  • Nevro Corp.$178
  • Nalu Medical, Inc.$177
  • AbbVie$164
  • plus $340 from 8 others

What the payments were for

  • Travel & lodging$1,33325%
  • Food & beverage$4,05775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,391 in reported general payments places this provider in the 50th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$731,590
Medicare patients
1,113
Services billed
12,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,308$33,659
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen731$29,726
Buprenorphine68$14,085
BelbucaBuprenorphine Hcl18$11,406
Pregabalin263$5,739
Tramadol Hcl ErTramadol Hcl51$3,391
Morphine Sulfate ErMorphine Sulfate144$2,891
Naloxone Hcl34$2,024
Gabapentin100$1,680
Oxycodone Hcl96$1,250
Tramadol Hcl134$1,237
Methadone Hcl83$1,038
Hydromorphone Hcl64$832
Diclofenac Sodium58$625
Cyclobenzaprine Hcl36$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$22$11,40618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →